SARA CROS COSTA

Profesora Asociada i Coordinadora d'Oncologia Clínica

Universitat Internacional de Catalunya

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Cancer Biology Cancer Biology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Sara Cros Costa is an Associate Professor and Coordinator of Clinical Oncology at Universitat Internacional de Catalunya, Spain. Her research primarily focuses on metastatic hormone-sensitive prostate cancer, specifically in the development and validation of prognostic and predictive gene expression signatures. She has contributed significantly to understanding the molecular profiling of cancer treatments, as evidenced by her recent publications on the clinical outcomes associated with various therapeutic strategies.

Articles (6)

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (1)

Anna Esteve

Institut Català d'Oncologia

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

SARA CROS COSTA

Research Interests

Explore related searches

Contact this professor

About

Articles (6)

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients

Molecular profiling and clinical relevance of low <i>PTEN</i> expression in patients with metastatic hormone-sensitive prostate cancer.

Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC).

Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.

Collaborators (1)

Anna Esteve

Make your next move.